MEDP vs SLP
MEDP: Medpace is a mid-sized, scientifically-focused global CRO that provides full-service clinical trial management for drug and medical device development. SLP: Simulations Plus provides advanced modeling and simulation software and services to accelerate drug discovery and clinical development for the life sciences industry.
Side-by-side fundamentals
| Metric | MEDP | SLP | Edge |
|---|---|---|---|
| Price as of 2026-07-23 close | $605.82 | $18.33 | |
| Market cap as of 2026-07-24 | $17.4B | $370M | |
| P/E as of 2026-07-24 | 37.69 | 45.65 | MEDP lower |
| PEG as of 2026-07-24 | 2.71 | n/a | |
| Net margin as of 2026-07-24 | +17.2% | +9.9% | MEDP higher |
| Gross margin as of 2026-07-24 | +29.1% | +63.4% | SLP higher |
| Operating margin as of 2026-07-24 | +21.0% | +14.0% | MEDP higher |
| ROE as of 2026-07-24 | +120.9% | +6.2% | MEDP higher |
| ROA as of 2026-07-24 | +24.8% | +5.7% | MEDP higher |
| Debt / equity as of 2026-07-24 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-24 | +24.2% | +2.1% | MEDP higher |
| Revenue CAGR (3y) SEC XBRL | +20.1% | +13.7% | MEDP higher |
| Dividend yield as of 2026-07-24 | n/a | +0.6% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-24 | 1.13 | 1.33 | |
| 1-year return as of 2026-07-23 close | +38.5% | +38.1% | MEDP higher |
Fundamentals: Finnhub, as of 2026-07-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-23.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.